Valeant Pharmaceuticals International, Inc. Form 3 January 04, 2017 FORM 3 UNITED STATES SEC

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> DE SCHUTTER RICHARD U			2. Date of Event Requiring Statement (Month/Day/Year) 01/02/2017	<sup>3</sup> 3. Issuer Name <b>and</b> Ticker or Trading Symbol Valeant Pharmaceuticals International, Inc. [VRX]				
(Last) (F	(First) (Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)			5. If Amendment, Date Original Filed(Month/Day/Year)	
400 SOMERSET CORPORATE BOULEVARD								
(Street) BRIDGEWATER, NJ 08807			X_ Director 10% Owner Officer Other (give title below) (specify below)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One			
(City) (S	State)	(Zip)	Table I - N	Jon-Derivat	ive Securit	ies Be	Reporting Person neficially Owned	
1.Title of Security (Instr. 4)		2. Amount of Beneficially (Instr. 4)			ture of Indirect Beneficial ership . 5)			
Common Stock,	, no par v	value	4,000		D	Â		
Reminder: Report o owned directly or in	ndirectly. Persons informa	s who resp ition conta	ch class of securities benefici bond to the collection of ined in this form are not nd unless the form displa	31	EC 1473 (7-02	2)		
Table	current	ly valid ON	ities Beneficially Owned (e.		warrants, op	tions, c	onvertible securities)	

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

OMB APPROVAL

Estimated average burden hours per

3235-0104

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 3

Date	Expiration	Title	Amount or	Security	Direct (D)
Exercisable	Date		Number of		or Indirect
			Shares		(I)
					(Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
DE SCHUTTER RICHARD U 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER, NJ 08807	X	Â	Â	Â	
Signatures					
Kelly Webber for Richard U. DeSchutter 01/04	4/2017				
**Signature of Reporting Person	Date				

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.